Longitudinal Analysis of Pharmacogenomic Variability in Antidepressant Metabolism and Its Relationship with Treatment Outcomes in Major Depressive Disorder
Keywords:
Major Depressive Disorder, Antidepressants, Pharmacogenomics, Cytochrome P450, Drug Metabolism, CYP2D6, CYP2C19, Treatment Outcomes, Genetic Polymorphisms, Personalized MedicineAbstract
Pharmacogenomic variability in antidepressant metabolism plays a crucial role in the differential effectiveness and side-effect profiles of antidepressant therapies in patients with Major Depressive Disorder (MDD). This study investigates the longitudinal relationship between genetic variations in drug-metabolizing enzymes, primarily cytochrome P450 enzymes, and the clinical outcomes of antidepressant treatment in MDD. By analyzing genetic polymorphisms in enzymes such as CYP2D6 and CYP2C19, the study provides insight into how these variations impact treatment responses. Our findings suggest that personalized treatment strategies, informed by pharmacogenomic testing, may improve therapeutic outcomes and reduce adverse effects in MDD patients. This research underscores the importance of considering pharmacogenomic data in clinical decision-making to optimize antidepressant therapy for MDD.
References
[1] Bousman, C. A., et al. (2018). The role of cytochrome P450 enzymes in antidepressant treatment: Implications for clinical practice. Pharmacogenomics, 19(7), 557-567.
[2] Wang, L., et al. (2019). CYP2C19 polymorphisms and antidepressant drug metabolism: A systematic review. Journal of Clinical Psychopharmacology, 39(4), 415-423.
[3] Mrazek, D. A., et al. (2014). Pharmacogenomic testing to guide antidepressant treatment in major depressive disorder. JAMA Psychiatry, 71(10), 1093-1101.
[4] Hicks, J. K., et al. (2012). Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 and 2C19 genotypes and antidepressant therapy. Clinical Pharmacology & Therapeutics, 91(2), 253-258.
[5] Desta, Z., et al. (2007). Clinical relevance of pharmacogenetics of the cytochrome P450 system. Pharmacological Reviews, 59(1), 63-67.
[6] López-Fernández, L. A., et al. (2019). Pharmacogenetic testing for antidepressants in clinical practice: A comprehensive review. Psychiatry Research, 275, 246-253.
[7] Lynch, T., & Price, A. (2007). The effect of cytochrome P450 metabolism on drug response and toxicity. American Family Physician, 76(3), 391-396.
[8] Bousman, C. A., et al. (2013). A systematic review and meta-analysis of the relationship between CYP2D6 genotype and antidepressant response in major depression. Pharmacogenomics Journal, 13(5), 361-367.
[9] Parker, V. G., et al. (2017). CYP2C19 and CYP2D6 genotyping in antidepressant therapy: A pharmacogenetic study. Journal of Clinical Psychopharmacology, 37(5), 575-581.
[10] Mrazek, D. A., et al. (2016). Clinical utility of pharmacogenomic testing for antidepressants. American Journal of Psychiatry, 173(11), 1160-1167.
Downloads
Published
Issue
Section
License
Copyright (c) -1 F. R. Wollheim (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
